Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

Open access
Bottini, Alberto, Generali, Daniele, Brizzi, Maria Pia, Fox, Stephen B., Bersiga, Alessandra, Bonardi, Simone, Allevi, Giovanni, Aguggini, Sergio, Bodini, Giuliana, Milani, Manuela, Dionisio, Rossana, Bernardi, Claudio, Montruccoli, Arianna, Bruzzi, Paolo, Harris, Adrian L., Dogliotti, Luigi, Berruti, Alfredo · 2006 · Journal of Clinical Oncology

Abstract

Purpose: To investigate the activity of letrozole plus/minus oral metronomic cyclophophamide as primary systemic treatment (PST) in elderly breast cancer patients. Methods: One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor–positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for 6 months) or a combination of letrozole plus oral cyclophosphamide (50 mg/daily for 6 months) in an open-labeled, randomized phase II trial. Tumor response was assessed clinically, and tumor Ki67 index and vascular endothelial growth factor (VEGF) -A levels were measured before and after treatment. Results: Overall response rate was 71.9% (95% CI, 60.0 to 83.8) in the 57 patients randomly assigned to receive primary letrozole and 87.7% (95% CI, 78.6 to 96.2) in the 57 patients randomly assigned to receive letrozole plus cyclophosphamide. The difference in activity between treatment arms was predominantly confined to patients with ductal histology. There was a significantly greater suppression of Ki67 and VEGF-A expression in the letrozole/cyclophosphamide-treated group than in the letrozole-treated group, leading to lower Ki67 and VEGF expression at post-treatment residual histology (P = .03 and P = .002, respectively). Conclusion: Both letrozole and letrozole plus cyclophosphamide treatments appeared active as PST in elderly breast cancer patients. Metronomic scheduling of cyclophosphamide may have an antiangiogenetic effect and the combination of letrozole plus cyclophosphamide warrants testing in a randomized phase III trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.5773

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 189

Metadata

Authors
Bottini, A., Generali, D., Brizzi, M. P., Fox, S. B., Bersiga, A., Bonardi, S., Allevi, G., Aguggini, S., Bodini, G., Milani, M., Dionisio, R., Bernardi, C., Montruccoli, A., Bruzzi, P., Harris, A. L., Dogliotti, L., & Berruti, A.
Venue
Journal of Clinical Oncology
Published
2006-08-01
Volume
24
Issue
22
Pages
3623-3628
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163940216
Cited by
189
References
1
FWCI
5.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. https://app.cochat.ai/papers/10.1200/jco.2005.04.5773
The paper
Bottini, A., Generali, D., Brizzi, M. P., Fox, S. B., Bersiga, A., Bonardi, S., Allevi, G., Aguggini, S., Bodini, G., Milani, M., Dionisio, R., Bernardi, C., Montruccoli, A., Bruzzi, P., Harris, A. L., Dogliotti, L., & Berruti, A. (2006). Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.5773

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.